HNGE Rallies 64.6% in 3 Months as Growth and Margins Gain Momentum

Hinge Health, Inc. HNGE has surged 64.6% over the past three months, sharpening the question of whether operating momentum can keep pace with rising investor expectations.

Second-quarter 2026 results support the rally. Revenues, billings and profitability improved sharply, while management raised its full-year outlook. The stronger setup also leaves less room for execution misses.

HNGE's Revenue Momentum Supports the Rally

Second-quarter revenues increased 53% year over year to $212.8 million. Last-12-month calculated billings rose to $861.8 million from $568.4 million a year earlier.

The client base expanded to 2,929 from 2,359. Management said better-than-expected billings were driven by stronger yield, while eligible lives and average selling price tracked prior expectations.

Image Source: Zacks Investment Research

Hinge Health's Margins Strengthen the Bull Case

Adjusted gross profit climbed 60.7% year over year to $185.3 million. Adjusted gross margin expanded 400 basis points to 87%, showing that rapid growth is translating into stronger profitability.

Adjusted operating income increased 135.7% to $61.5 million. The adjusted operating margin reached 29%, up 1,000 basis points year over year, while free cash flow totaled about $100 million in the quarter.

HNGE's Raised Outlook Lifts Expectations Further

Hinge Health raised full-year 2026 revenue guidance to $856-$860 million from $798-$804 million. Adjusted operating income guidance increased to $236-$244 million from $217-$227 million.

Management now expects full-year yield of about 4.45%. Third-quarter revenue guidance of $223-$225 million implies 45% year-over-year growth at the midpoint, keeping the near-term growth bar elevated.

Hinge Health Has More Routes to Extend Growth

Migraine adoption reached more than 450 clients covering more than 5 million eligible lives. HingeSelect also expanded beyond 5,000 provider locations, broadening the company’s reach across care pathways.

The planned $105 million acquisition of Cylinder Health adds gastrointestinal care, nearly 100 clients and about 2 million lives. Omada Health, Inc. OMDA also addresses musculoskeletal and cardiometabolic conditions, highlighting the broader push toward multi-condition virtual care.

HNGE's Rally Leaves Less Room for Execution Misses

The raised outlook depends increasingly on yield, renewals and sales-pipeline conversion. Hinge Health must also integrate Cylinder, invest ahead of a broader gastrointestinal rollout and maintain commercial momentum as expectations rise.

Competition for employer and health-plan budgets remains relevant. Teladoc Health, Inc. TDOC markets integrated virtual-care offerings across several care categories, reinforcing the need for Hinge Health to sustain differentiation, partner access and implementation quality.

HNGE's Neutral Signal Keeps the 64.6% Gain in Check

The 64.6% three-month advance is backed by faster revenues, wider margins and a higher 2026 outlook. The counterweight is a tougher execution hurdle as Hinge Health expands into new programs and allocates capital across growth, acquisitions and repurchases.

HNGE currently carries a Zacks Rank #3 (Hold). That rating supports a balanced stance rather than a clear near-term buy signal. HNGE’s Style Scores present a mixed picture. The stock has a Growth Score of A, highlighting favorable growth prospects, but its D Value Score suggests that the shares are not particularly attractive on valuation metrics.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research